Scholarlink

Objective <p>To compare the comparative efficacy and safety of leukocyte-rich platelet-rich plasma (L-PRP), leukocyte-poor platelet-rich plasma (LP-PRP), hyaluronic acid (HA), and placebo for the treatment of knee osteoarthritis (KOA).</p> Design <p>Systematic review and network meta-analysis of randomized controlled trials (RCTs).</p> Data sources <p>A comprehensive search of PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science was conducted from inception to October 2025, without language restrictions.</p> Eligibility criteria for selecting studies <p>We included RCTs that compared at least two of the following interventions in patients with KOA: L-PRP, LP-PRP, HA, or placebo. The primary outcome was functional improvement measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Secondary outcomes were pain reduction and the incidence of short-term adverse events.</p> Results <p>Twenty-one RCTs, comprising 2,254 patients, were included. The network meta-analysis demonstrated that for functional improvement at 6–12 months, both L-PRP (Mean Difference [MD] vs. placebo: −13.20; 95% Confidence Interval [CI]: −20.80 to -5.60) and LP-PRP (MD: −10.54; 95% CI: −18.37 to -2.71) were significantly superior to placebo. Both were also superior to HA. According to P-score rankings, LP-PRP was the most effective treatment for function (0.96), followed by L-PRP (0.82). However, the direct comparison between LP-PRP and L-PRP showed no statistically significant difference in efficacy. For pain reduction, all active treatments were superior to placebo. While L-PRP was associated with a higher incidence of transient local adverse events, the data were inconsistently reported. Sensitivity analyses confined to studies with a low risk of bias confirmed the robustness of these findings.</p> Conclusion <p>Intra-articular PRP provides clinically significant functional improvement and pain relief for patients with KOA, with an efficacy superior to that of HA. Both L-PRP and LP-PRP are effective treatment options with comparable efficacy based on current evidence. Although qualitative trends suggest a potentially better safety profile for LP-PRP, robust data are lacking. Therefore, there is insufficient evidence to recommend one PRP formulation over the other.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月2日

查看全文
  • Bing Xu,
  • Xinyun Huang,
  • Xiaojie Su,
  • Yangyang Fu,
  • Shengyi Feng,
  • Ya Zhou,
  • Li Gong,
  • Juntao Yan,
  • Li Gong,
  • Juntao Yan

摘要

Objective

To compare the comparative efficacy and safety of leukocyte-rich platelet-rich plasma (L-PRP), leukocyte-poor platelet-rich plasma (LP-PRP), hyaluronic acid (HA), and placebo for the treatment of knee osteoarthritis (KOA).

Design

Systematic review and network meta-analysis of randomized controlled trials (RCTs).

Data sources

A comprehensive search of PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science was conducted from inception to October 2025, without language restrictions.

Eligibility criteria for selecting studies

We included RCTs that compared at least two of the following interventions in patients with KOA: L-PRP, LP-PRP, HA, or placebo. The primary outcome was functional improvement measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Secondary outcomes were pain reduction and the incidence of short-term adverse events.

Results

Twenty-one RCTs, comprising 2,254 patients, were included. The network meta-analysis demonstrated that for functional improvement at 6–12 months, both L-PRP (Mean Difference [MD] vs. placebo: −13.20; 95% Confidence Interval [CI]: −20.80 to -5.60) and LP-PRP (MD: −10.54; 95% CI: −18.37 to -2.71) were significantly superior to placebo. Both were also superior to HA. According to P-score rankings, LP-PRP was the most effective treatment for function (0.96), followed by L-PRP (0.82). However, the direct comparison between LP-PRP and L-PRP showed no statistically significant difference in efficacy. For pain reduction, all active treatments were superior to placebo. While L-PRP was associated with a higher incidence of transient local adverse events, the data were inconsistently reported. Sensitivity analyses confined to studies with a low risk of bias confirmed the robustness of these findings.

Conclusion

Intra-articular PRP provides clinically significant functional improvement and pain relief for patients with KOA, with an efficacy superior to that of HA. Both L-PRP and LP-PRP are effective treatment options with comparable efficacy based on current evidence. Although qualitative trends suggest a potentially better safety profile for LP-PRP, robust data are lacking. Therefore, there is insufficient evidence to recommend one PRP formulation over the other.